Question 1

What is Alnylam Pharmaceuticals's P/S ratio?

Accepted Answer

Alnylam Pharmaceuticals (ALNY) P/S ratio is 8.6× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month revenue, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/S ratio calculated?

Accepted Answer

P/S = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Revenue, or equivalently Share Price ÷ TTM Revenue Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/S ratio?

Accepted Answer

The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.

Question 4

What is a good P/S ratio for Alnylam Pharmaceuticals?

Accepted Answer

A "good" P/S depends heavily on profit margin and growth: software and other high-margin businesses often command 5–15× sales, while low-margin retailers and commodity producers typically trade below 1×. Compare against sector peers rather than absolute thresholds. For Alnylam Pharmaceuticals specifically, the relevant sector benchmark is the current sector median of 3.4×.

Question 5

Is Alnylam Pharmaceuticals's P/S ratio high or low?

Accepted Answer

Alnylam Pharmaceuticals's P/S ratio of 8.6× is below its own 5-year average of 18.7× and above the sector median of 3.4×. That places the current reading at the 0th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Alnylam Pharmaceuticals's historical P/S ratio range?

Accepted Answer

In the available daily series, Alnylam Pharmaceuticals (ALNY) P/S ratio has ranged from a low of 3.4× in 2011 to a high of 194.4× in 2015. The 5-year average is 18.7× and the 5-year median is 17.9×.

Question 7

What was Alnylam Pharmaceuticals's P/S ratio in 2025?

Accepted Answer

Alnylam Pharmaceuticals (ALNY) P/S ratio at the end of 2025 was 14.2×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month revenue figure available at that date.

Question 8

Why does Alnylam Pharmaceuticals's P/S ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (revenue). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$52.6B	$3.71B	14.2×	+0.7×	Dec 31, 2025
2024	$30.3B	$2.25B	13.5×	+0.3×	Dec 31, 2024
2023	$24B	$1.83B	13.2×	-15.1×	Dec 31, 2023
2022	$29.3B	$1.04B	28.2×	+4.2×	Dec 31, 2022
2021	$20.3B	$844M	24.1×	-6.6×	Dec 31, 2021
2020	$15.1B	$493M	30.7×	-27.9×	Dec 31, 2020
2019	$12.9B	$220M	58.6×	-39.8×	Dec 31, 2019
2018	$7.37B	$74.9M	98.4×	-37.5×	Dec 31, 2018
2017	$12.2B	$89.9M	135.8×	+67.7×	Dec 31, 2017
2016	$3.21B	$47.2M	68.2×	-126.3×	Dec 31, 2016
2015	$7.99B	$41.1M	194.4×	+46.8×	Dec 31, 2015
2014	$7.46B	$50.6M	147.6×	+61.9×	Dec 31, 2014
2013	$4.05B	$47.2M	85.8×	+71.6×	Dec 31, 2013
2012	$946M	$66.7M	14.2×	+9.6×	Dec 31, 2012
2011	$377M	$82.8M	4.6×	+0.4×	Dec 31, 2011
2010	$416M	$100M	4.2×	-3.2×	Dec 31, 2010
2009	$738M	$101M	7.3×	-3.3×	Dec 31, 2009
2008	$1.02B	$96.2M	10.6×	-12.6×	Dec 31, 2008
2007	$1.18B	$50.9M	23.2×	-6.5×	Dec 31, 2007
2006	$800M	$26.9M	29.7×	-40.5×	Dec 31, 2006
2005	$401M	$5.72M	70.2×	+34.5×	Dec 31, 2005
2004	$153M	$4.28M	35.7×	-77.4×	Dec 31, 2004
2003	$9.95M	$88K	113.0×	—	Dec 31, 2003


Zimmer Biomet Holdings (ZBH)	2.1×
AptarGroup (ATR)	2.1×
Becton, Dickinson and (BDX)	2.1×
Charles River (CRL)	1.9×
Quest Diagnostics (DGX)	1.9×
IQVIA (IQV)	1.7×
GE HealthCare (GEHC)	1.6×
Labcorp Holdings (LH)	1.6×
HCA Healthcare (HCA)	1.4×
Solventum (SOLV)	1.4×
Viatris (VTRS)	1.1×
UnitedHealth Group (UNH)	0.8×
Baxter International (BAX)	0.8×
DaVita (DVA)	0.7×
Henry Schein (HSIC)	0.6×
Universal Health Services (UHS)	0.6×
Elevance Health (ELV)	0.4×
Teladoc Health (TDOC)	0.4×
McKesson (MCK)	0.3×
Cigna (CI)	0.3×
CVS Health (CVS)	0.2×
Cardinal Health (CAH)	0.2×
Cencora (COR)	0.2×
Humana (HUM)	0.2×
Centene (CNC)	0.1×

P/S Ratio for Alnylam Pharmaceuticals (ALNY) 2003-2026

P/S Ratio daily chart for Alnylam Pharmaceuticals (ALNY)

Historical P/S Ratio for Alnylam Pharmaceuticals (ALNY) from 2003 to 2025

About P/S Ratio at Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals P/S Ratio by Year

Alnylam Pharmaceuticals P/S Ratio 2025: 14.2×

Alnylam Pharmaceuticals P/S Ratio 2024: 13.5×

Alnylam Pharmaceuticals P/S Ratio 2023: 13.2×

Alnylam Pharmaceuticals P/S Ratio 2022: 28.2×

Alnylam Pharmaceuticals P/S Ratio 2021: 24.1×

Sector peers by P/S Ratio — chart

Sector peers by P/S Ratio — table

Frequently asked questions

Alnylam Pharmaceuticals (ALNY) Key Financials